These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 21424701)

  • 1. A phase I trial of MK-0731, a kinesin spindle protein (KSP) inhibitor, in patients with solid tumors.
    Holen K; DiPaola R; Liu G; Tan AR; Wilding G; Hsu K; Agrawal N; Chen C; Xue L; Rosenberg E; Stein M
    Invest New Drugs; 2012 Jun; 30(3):1088-95. PubMed ID: 21424701
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase I, dose-escalation study of the Eg5-inhibitor EMD 534085 in patients with advanced solid tumors or lymphoma.
    Hollebecque A; Deutsch E; Massard C; Gomez-Roca C; Bahleda R; Ribrag V; Bourgier C; Lazar V; Lacroix L; Gazzah A; Varga A; de Baere T; Beier F; Kroesser S; Trang K; Zenke FT; Klevesath M; Soria JC
    Invest New Drugs; 2013 Dec; 31(6):1530-8. PubMed ID: 24077982
    [TBL] [Abstract][Full Text] [Related]  

  • 3. First-in-human phase 1 study of filanesib (ARRY-520), a kinesin spindle protein inhibitor, in patients with advanced solid tumors.
    LoRusso PM; Goncalves PH; Casetta L; Carter JA; Litwiler K; Roseberry D; Rush S; Schreiber J; Simmons HM; Ptaszynski M; Sausville EA
    Invest New Drugs; 2015 Apr; 33(2):440-9. PubMed ID: 25684345
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A first in human study of SB-743921, a kinesin spindle protein inhibitor, to determine pharmacokinetics, biologic effects and establish a recommended phase II dose.
    Holen KD; Belani CP; Wilding G; Ramalingam S; Volkman JL; Ramanathan RK; Vasist LS; Bowen CJ; Hodge JP; Dar MM; Ho PT
    Cancer Chemother Pharmacol; 2011 Feb; 67(2):447-54. PubMed ID: 20461380
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase I study of ispinesib, a kinesin spindle protein inhibitor, administered weekly for three consecutive weeks of a 28-day cycle in patients with solid tumors.
    Burris HA; Jones SF; Williams DD; Kathman SJ; Hodge JP; Pandite L; Ho PT; Boerner SA; Lorusso P
    Invest New Drugs; 2011 Jun; 29(3):467-72. PubMed ID: 20069338
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Phase I study to assess the safety, tolerability, and pharmacokinetics of AZD4877, an intravenous Eg5 inhibitor in patients with advanced solid tumors.
    Infante JR; Kurzrock R; Spratlin J; Burris HA; Eckhardt SG; Li J; Wu K; Skolnik JM; Hylander-Gans L; Osmukhina A; Huszar D; Herbst RS
    Cancer Chemother Pharmacol; 2012 Jan; 69(1):165-72. PubMed ID: 21638123
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase 1 open-label, sequential dose-escalation study investigating the safety, tolerability, and pharmacokinetics of intravenous TLC388 administered to patients with advanced solid tumors.
    Ghamande S; Lin CC; Cho DC; Shapiro GI; Kwak EL; Silverman MH; Tseng Y; Kuo MW; Mach WB; Hsu SC; Coleman T; Yang JC; Cheng AL; Ghalib MH; Chuadhary I; Goel S
    Invest New Drugs; 2014 Jun; 32(3):445-51. PubMed ID: 24271274
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I trial of continuous infusion 9-aminocamptothecin in patients with advanced solid tumors: 21-day infusion is an active well-tolerated regimen.
    Sewak S; Sorich J; O'Leary J
    Anticancer Drugs; 2006 Jun; 17(5):571-9. PubMed ID: 16702815
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A dose-finding, pharmacokinetic and pharmacodynamic study of a novel schedule of flavopiridol in patients with advanced solid tumors.
    Ramaswamy B; Phelps MA; Baiocchi R; Bekaii-Saab T; Ni W; Lai JP; Wolfson A; Lustberg ME; Wei L; Wilkins D; Campbell A; Arbogast D; Doyle A; Byrd JC; Grever MR; Shah MH
    Invest New Drugs; 2012 Apr; 30(2):629-38. PubMed ID: 20938713
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I clinical trial and pharmacokinetic study of the spicamycin analog KRN5500 administered as a 1-hour intravenous infusion for five consecutive days to patients with refractory solid tumors.
    Supko JG; Eder JP; Ryan DP; Seiden MV; Lynch TJ; Amrein PC; Kufe DW; Clark JW
    Clin Cancer Res; 2003 Nov; 9(14):5178-86. PubMed ID: 14613997
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I trial of UCN-01 in combination with topotecan in patients with advanced solid cancers: a Princess Margaret Hospital Phase II Consortium study.
    Hotte SJ; Oza A; Winquist EW; Moore M; Chen EX; Brown S; Pond GR; Dancey JE; Hirte HW
    Ann Oncol; 2006 Feb; 17(2):334-40. PubMed ID: 16284058
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I dose escalation study of MK-0457, a novel Aurora kinase inhibitor, in adult patients with advanced solid tumors.
    Traynor AM; Hewitt M; Liu G; Flaherty KT; Clark J; Freedman SJ; Scott BB; Leighton AM; Watson PA; Zhao B; O'Dwyer PJ; Wilding G
    Cancer Chemother Pharmacol; 2011 Feb; 67(2):305-14. PubMed ID: 20386909
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase I trial to determine the safety, pharmacokinetics, and pharmacodynamics of intercalated BMS-690514 with paclitaxel/carboplatin (PC) in advanced or metastatic solid malignancies.
    Chow LQ; Jonker DI; Dy GK; Nicholas G; Fortin C; Patricia D; Adjei AA; Belani CP; Gupta A; Park JS; Zhang S; Sbar EI; Laurie SA
    Cancer Chemother Pharmacol; 2013 May; 71(5):1273-85. PubMed ID: 23468081
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I and pharmacokinetic study of BMS-188797, a new taxane analog, administered on a weekly schedule in patients with advanced malignancies.
    Advani R; Fisher GA; Lum BL; Jambalos C; Cho CD; Cohen M; Gollerkeri A; Sikic BI
    Clin Cancer Res; 2003 Nov; 9(14):5187-94. PubMed ID: 14613998
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I study of TZT-1027, a novel synthetic dolastatin 10 derivative and inhibitor of tubulin polymerization, which was administered to patients with advanced solid tumors on days 1 and 8 in 3-week courses.
    Tamura K; Nakagawa K; Kurata T; Satoh T; Nogami T; Takeda K; Mitsuoka S; Yoshimura N; Kudoh S; Negoro S; Fukuoka M
    Cancer Chemother Pharmacol; 2007 Jul; 60(2):285-93. PubMed ID: 17136542
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety, pharmacokinetics, and activity of GRN1005, a novel conjugate of angiopep-2, a peptide facilitating brain penetration, and paclitaxel, in patients with advanced solid tumors.
    Kurzrock R; Gabrail N; Chandhasin C; Moulder S; Smith C; Brenner A; Sankhala K; Mita A; Elian K; Bouchard D; Sarantopoulos J
    Mol Cancer Ther; 2012 Feb; 11(2):308-16. PubMed ID: 22203732
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase 1 trial and pharmacokinetic study of the oral platinum analog satraplatin in children and young adults with refractory solid tumors including brain tumors.
    Akshintala S; Marcus L; Warren KE; Murphy RF; Sissung TM; Srivastava A; Goodspeed WJ; Goodwin A; Brewer CC; Zalewski C; King KA; Kim A; Figg WD; Widemann BC
    Pediatr Blood Cancer; 2015 Apr; 62(4):603-10. PubMed ID: 25556988
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I clinical and pharmacokinetic study of flavopiridol administered as a daily 1-hour infusion in patients with advanced neoplasms.
    Tan AR; Headlee D; Messmann R; Sausville EA; Arbuck SG; Murgo AJ; Melillo G; Zhai S; Figg WD; Swain SM; Senderowicz AM
    J Clin Oncol; 2002 Oct; 20(19):4074-82. PubMed ID: 12351605
    [TBL] [Abstract][Full Text] [Related]  

  • 19. First-in-human phase I dose escalation study of MK-8033 in patients with advanced solid tumors.
    Keedy VL; Lenz HJ; Saltz L; Whisenant JG; Berlin JD; Camacho LH
    Invest New Drugs; 2018 Oct; 36(5):860-868. PubMed ID: 29376210
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I and pharmacokinetic study of the dolastatin-15 analogue tasidotin (ILX651) administered intravenously on days 1, 3, and 5 every 3 weeks in patients with advanced solid tumors.
    Cunningham C; Appleman LJ; Kirvan-Visovatti M; Ryan DP; Regan E; Vukelja S; Bonate PL; Ruvuna F; Fram RJ; Jekunen A; Weitman S; Hammond LA; Eder JP
    Clin Cancer Res; 2005 Nov; 11(21):7825-33. PubMed ID: 16278405
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.